article thumbnail

The real-world incidence of severe QT prolongation in patients taking antipsychotic drugs

HeartRhythm

The increased risk of arrhythmias and sudden cardiac death (SCD) caused by drug-induced QT prolongation has been a prominent safety pharmacology concern for the last 30 years.

article thumbnail

PO-05-201 PHARMACOLOGICAL MODULATION OF THE ARRHYTHMIC SUBSTRATE IN TIMOTHY SYNDROME: A PORCINE MODEL STUDY

HeartRhythm

Contemporary antiarrhythmic treatment of Timothy syndrome 1 (TS1) is inadequate to prevent sudden cardiac death. Using electroanatomic mapping (EAM) we discovered cardiac activation delay, which creates the milieu for functional reentrant ventricular arrhythmias.

article thumbnail

Ajmaline Infusion for Unmasking Short-Coupled Purkinje Ectopy: Need for Speed?

HeartRhythm

Recent reports have spotlighted the potential of pharmacological tests with sodium channel blockers (SCB) in unmasking short-coupled premature ventricular contractions (ScPVCs), most frequently of Purkinje origin, in patients at risk for sudden cardiac death (SCD).1,2

article thumbnail

Hydroxychloroquine and Chloroquine-Induced Cardiac Arrhythmias and Sudden Cardiac Death in Patients with Systemic Autoimmune Rheumatic Diseases: A Systematic Review and Meta-Analysis

Journal of Cardiovascular Pharmacology

Concerns regarding the risk of cardiac arrhythmia and death have been raised, yet the burden of HCQ and CQ-related cardiac toxicities remains unclear.

article thumbnail

American College of Cardiology (ACC) and American Heart Association (AHA) Issue New Hypertrophic Cardiomyopathy (HCM) Management Guidelines

DAIC

New HCM Guidelines Updated recommendations in the guideline reflect recent evidence about HCM treatment and management including new forms of pharmacologic management; participation in vigorous recreational activities and competitive sports; and risk stratification for sudden cardiac death (SCD) with an emphasis on pediatric patients.

article thumbnail

Lowering Atherosclerotic Cardiovascular Disease Events by Treating Residual Inflammatory Risk

DAIC

21-23 hsCRP is nonspecific inflammatory marker and an acute phase reactant that predicts the likelihood of a heart attack, stroke, peripheral artery disease and sudden cardiac death among healthy individuals with no history of CV disease, and recurrent events and death in patients with known ASCVD.22 2015;45(3):341-350.